2014
Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?
Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.Peer-Reviewed Original ResearchMargin statusIntraoperative imagingFinal margin statusMedian tumor sizeBreast cancer patientsRe-excision ratesIntraoperative specimen radiographyCohort of interestIntraoperative marginsResidual tumorPartial mastectomyPositive marginsProspective studyTumor sizeCancer patientsInvasive cancerFurther excisionPathology resultsIntraoperative resectionPatientsDefinitive specimenSpecimen radiographyIntraoperative specimenSurgeons
2012
Predictors of residual disease after breast-conserving surgery.
Aneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of residual disease after breast-conserving surgery. Journal Of Clinical Oncology 2012, 30: 168-168. DOI: 10.1200/jco.2012.30.27_suppl.168.Peer-Reviewed Original ResearchResidual invasive diseaseResidual invasive cancerResidual DCISInvasive cancerInvasive diseaseResidual diseaseMargin distanceSitu diseaseTumor sizeBreast cancerRetrospective cohort studyInvasive breast cancerBreast-conserving surgerySitu breast cancerCavity shave marginsMain outcome variablesCohort of interestLocoregional failureChart reviewCohort studyLymphovascular invasionPathologic factorsAdditional resectionPostoperative managementRisk stratification
2011
P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.Peer-Reviewed Original ResearchSerum cytokine levelsHormone receptor statusLymph node statusCytokine levelsReceptor statusTumor sizeBreast cancer behaviorSerum cytokinesNode statusCancer behaviorIFN-gamma serum levelsMedian patient ageMedian tumor sizeSerum IFN-gammaSerum inflammatory cytokinesProgesterone receptor statusRole of inflammationFinal pathologic resultsPresence of metastasesBreast cancer patientsBreast cancer developmentVariety of cytokinesCohort of interestLymphovascular invasionPatient ageP3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.Peer-Reviewed Original ResearchDuctal intraepithelial neoplasiaHormone receptor statusReceptor statusNuclear gradeIntraepithelial neoplasiaSame tumorHormonal therapyDifferent nuclear gradesHospital tumor registryMedian patient ageMajority of patientsLobular intraepithelial neoplasiaDin-2DIN 1Cohort of interestDIN patientsPR positivityPatient ageER statusPR statusTumor RegistrySingle pathologistInvasive tumorsSame patientPatients
2009
Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes.
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Mamounas E, Giuliano A, Cook E, Wang S. Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes. Cancer Research 2009, 69: 302-302. DOI: 10.1158/0008-5472.sabcs-09-302.Peer-Reviewed Original ResearchAxillary node dissectionNon-SLN metastasisTumor sizeIntra-operative dataBLN AssayPositive SLNMedian numberLogistic regression modelsPositive non-sentinel lymph nodesSentinel lymph node-positive patientsCompletion axillary node dissectionFrozen sectionsLymph node-positive patientsNon-sentinel lymph nodesStepwise logistic regression modelFurther positive nodesNon-SLN statusMedian tumor sizeNode-positive patientsPositive rateTumor size dataSignificant predictorsCohort of interestNode dissectionPositive nodesUse of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN)
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Saha S, Julian T. Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN). Journal Of Clinical Oncology 2009, 27: 530-530. DOI: 10.1200/jco.2009.27.15_suppl.530.Peer-Reviewed Original ResearchSentinel lymph nodesLymph nodesFinal pathologyTumor sizeMedian cycle timeBreast cancer sentinel lymph nodesTotal lymph nodesMedian tumor sizePositive lymph nodesImmediate breast reconstructionHematoxylin-eosin stainingReceiver operator curveCohort of interestBLN AssayQuantitative RT-PCRSLN metastasisProspective studyBreast reconstructionReal-time RT-PCR analysisMedian numberClinical utilityRadiation therapyPatientsMultivariate analysisMammaglobinOptimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients
Reuter N, Bower M, Scoggins C, Martin R, McMasters K, Chagpar A. Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients. Journal Of Clinical Oncology 2009, 27: 611-611. DOI: 10.1200/jco.2009.27.15_suppl.611.Peer-Reviewed Original ResearchSentinel node biopsyBreast cancer patientsNode biopsySentinel nodesCancer patientsFalse negative rateOptimal timingFN rateSN identification rateMean tumor sizeProspective multicenter studyOverall false-negative rateNon-significant trendCohort of interestMulticenter studyTumor sizeMean ageSulfur colloidBreast cancerSN identificationPatientsInvasive meansNegative rateSignificant financial relationshipHot nodesFactors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.
Chagpar A, Lewis J, McMasters K, Edwards M. Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. Cancer Research 2009, 69: 4105. DOI: 10.1158/0008-5472.sabcs-4105.Peer-Reviewed Original ResearchAddition of chemotherapyHormone receptor-positive breast cancerReceptor-positive breast cancerAbsolute survival benefitAdjuvant hormonal therapyOverall survival benefitHormonal therapySurvival benefitOverall survivalAdjuvant chemotherapyClinicopathologic factorsAbsolute benefitBreast cancerHormone receptor-positive patientsReceptor-positive patientsTamoxifen Adjuvant trialMedian patient ageMedian tumor sizeMajority of patientsYears of ageCohort of interestAdjuvant trialsLymphovascular invasionPatient agePositive disease